GLP-1 RAs Beat Metformin for Dementia Prevention in T2D: Daily Dose

Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.

On July 24, 2025, we reported on a study published in BMJ Open Diabetes Research & Care that was designed to compare the effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and metformin in reducing the risk of dementia.

The study

Investigators conducted a retrospective cohort study using data from a global health research network between 2004 and 2024. Eligible individuals were adults with type 2 diabetes (T2D) without prior dementia who initiated either a GLP-1 RA or metformin as first-line treatment and had no history of insulin or other glucose-lowering drug use. Propensity score matching was applied to balance demographic and clinical variables between the treatment groups.

The findings

Among 87 229 matched patients per cohort, GLP- 1 RA use was associated with a significantly lower risk of overall dementia (adjusted HR (AHR) 0.90, 95% CI 0.85-0.95), Alzheimer disease (AD) (AHR 0.88, 95% CI 0.83-0.94), and nonvascular dementias (AHR 0.75, 95% CI 0.70-0.81) compared with metformin. No significant difference was observed for vascular dementias, according to the results.

Authors' comments

"These findings support the early use of GLP- 1 RAs in patients with T2DM at risk for cognitive decline and may influence future diabetes treatment guidelines to prioritize therapies with dual glycemic and neuroprotective benefits."

Click here for more details.